• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Fresenius, plaintiffs ask for more time for $250m settlement in dialysate cases

Fresenius, plaintiffs ask for more time for $250m settlement in dialysate cases

March 4, 2016 By Brad Perriello

Fresenius Medical CareFresenius Medical Care (NYSE:FMS) and the plaintiffs in a spate of lawsuits brought over its GranuFlo and NaturaLyte dialysis drugs yesterday asked a federal judge in Massachusetts to stay the case so they can finalize their $250 million settlement deal.

The deal, brokered with a committee of plaintiffs’ representatives, requires that 97% of all patients who brought lawsuits sign on by July. Fresenius said last month that if that bar is met, Fresenius Medical Care North America would fund the settlement in August, using $220 million from its insurers.

The company and the plaintiffs asked Judge Douglas Woodlock of the U.S. District Court for Massachusetts to stay the MDL until August 31 and postpone the trials of a the 1st pair of bellwether cases in the litigation.

“The requested stay of proceedings in this MDL and continuances of the 1st 2 bellwether trials are based upon good cause; they serve interests of judicial economy and promote litigation efficiency as the parties attempt to effectuate a settlement-in-principle as reported to the court on Feb. 17, 2016,” they wrote. “The parties are optimistic that the settlement will resolve the vast majority of the related cases. The requested stay and continuance would permit the parties to focus on resolution while also assuring a prompt resumption of the bellwether trial schedule in the event settlement fails.”

There are roughly 4,000 cases in the MDL, according to court documents. Discovery is complete in the 10 cases selected as bellwethers, according to the documents, but only the 1st 2 have been scheduled for trial. The parties asked Woodlock to schedule the 1st trial for October and December.

The GranuFlo and Naturalyte products were used to lower the acidity of patients’ blood during dialysis treatments. The lawsuits in the MDL generally allege that the dialysates’ high concentration of acetone led to abnormally high levels of bicarbonate in the blood, leading to fatal heart problems and strokes.

In 1 case, a dialysis patient in Kentucky named Linda Teague allegedly died at age 48 from cardiac arrest after a procedure there.

“Decedent received defendants’ defective product during that dialysis treatment and, on or about Jan. 14, 2011, suffered cardiac arrest and died from the injuries she sustained as a result of her exposure to defendants’ defective product,” according to the complaint. “Even though defendants knew of the risks for several years, medical providers were unaware that the high levels of bicarbonate in defendants’ products heighten the risk of cardiac injury by 6 times. As a result, thousands of patients receiving dialysis treatment were unknowingly overdosed.”

An internal Fresenius memo from November 2011 allegedly details the results of a study completed in 2010, “based on data defendants had available for many years,” according to the documents.

The FDA launched a Class I recall of FMC’s GranuFlo product in March 2012, after obtaining a copy of the memo, and and began investigating Fresenius later that year, after more than 900 patients experienced heart attacks at Fresenius dialysis centers.

Fresenius said it expects the settlement to deliver a pre-tax charge of $60 million, but stood pat on its guidance for 2015. The German dialysis giant said it expects to post sales of roughly $16.7 billion for 2015.

Filed Under: Dialysis, Legal News, Product Liability Tagged With: Fresenius

More recent news

  • Accelus wins FDA clearance for MRI compatibility of FlareHawk spinal implants
  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech
  • Neurent Medical wins FDA nod for next-gen chronic rhinitis treatment
  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy